Literature DB >> 8450526

Early side-effects of antihypertensive therapy: comparison of amlodipine and nifedipine retard.

A D Bremner1, P J Fell, J Hosie, I G James, P A Saul, S H Taylor.   

Abstract

In a multicentre crossover study of 97 patients with mild hypertension, the incidence and severity of adverse effects were observed during the first 14 days of treatment with amlodipine, nifedipine retard or placebo. Amlodipine (5 mg) once daily was equipotent to nifedipine retard (20 mg) twice daily. At these doses, the incidence of adverse effects was significantly greater during treatment with nifedipine retard (41%) than with amlodipine (27%, P < 0.05) or placebo (16%, P < 0.01). In particular, headache and flushing occurred significantly less frequently during the first 14 days of treatment with amlodipine than with nifedipine retard. The lower incidence and reduced severity of vasodilatory side-effects associated with amlodipine resulted in fewer withdrawals during initiation of therapy (2 on amlodipine compared with 7 on nifedipine retard).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8450526

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  4 in total

1.  Effects of cilnidipine, a novel dihydropyridine calcium antagonist, on autonomic function, ambulatory blood pressure and heart rate in patients with essential hypertension.

Authors:  J Minami; Y Kawano; Y Makino; H Matsuoka; S Takishita
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

2.  Comparison of once-daily nifedipine controlled-release with twice-daily nifedipine retard in the treatment of essential hypertension.

Authors:  Junichi Minami; Atsushi Numabe; Norikazu Andoh; Naohiko Kobayashi; Shigeo Horinaka; Toshihiko Ishimitsu; Hiroaki Matsuoka
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

Review 3.  Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease.

Authors:  M Haria; A J Wagstaff
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

4.  Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring.

Authors:  K Kubota; G L Pearce; W H Inman
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.